Compare PLETHICO PHARMA with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA DR. DATSONS LABS PLETHICO PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x -1.1 -10.9 - View Chart
P/BV x 0.0 0.2 10.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PLETHICO PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
DR. DATSONS LABS
Mar-14
PLETHICO PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs395126 314.4%   
Low Rs3131 101.3%   
Sales per share (Unadj.) Rs604.4133.0 454.5%  
Earnings per share (Unadj.) Rs32.50.2 21,422.5%  
Cash flow per share (Unadj.) Rs51.36.6 776.8%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.6128.8 367.7%  
Shares outstanding (eoy) m34.0831.66 107.6%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x0.40.6 59.9%   
Avg P/E ratio x6.6516.1 1.3%  
P/CF ratio (eoy) x4.211.8 35.1%  
Price / Book Value ratio x0.50.6 74.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,2622,477 293.1%   
No. of employees `000NANA-   
Total wages/salary Rs m1,59656 2,850.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,5984,211 489.2%  
Other income Rs m38679 490.9%   
Total revenues Rs m20,9844,289 489.2%   
Gross profit Rs m2,818569 495.5%  
Depreciation Rs m642204 314.2%   
Interest Rs m1,593430 370.3%   
Profit before tax Rs m96913 7,626.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1386 -2,268.5%   
Profit after tax Rs m1,1075 23,060.0%  
Gross profit margin %13.713.5 101.3%  
Effective tax rate %-14.348.0 -29.7%   
Net profit margin %5.40.1 4,713.8%  
BALANCE SHEET DATA
Current assets Rs m18,8776,852 275.5%   
Current liabilities Rs m11,8966,711 177.3%   
Net working cap to sales %33.93.3 1,012.0%  
Current ratio x1.61.0 155.4%  
Inventory Days Days36161 22.3%  
Debtors Days Days198318 62.1%  
Net fixed assets Rs m9,8613,673 268.5%   
Share capital Rs m341317 107.6%   
"Free" reserves Rs m12,3313,761 327.9%   
Net worth Rs m16,1394,078 395.8%   
Long term debt Rs m4,7061,671 281.6%   
Total assets Rs m33,14612,633 262.4%  
Interest coverage x1.61.0 156.2%   
Debt to equity ratio x0.30.4 71.2%  
Sales to assets ratio x0.60.3 186.4%   
Return on assets %8.13.4 236.6%  
Return on equity %6.90.1 5,826.2%  
Return on capital %12.37.7 160.2%  
Exports to sales %21.422.9 93.4%   
Imports to sales %15.214.3 106.5%   
Exports (fob) Rs m4,402964 456.7%   
Imports (cif) Rs m3,136602 521.0%   
Fx inflow Rs m4,402964 456.7%   
Fx outflow Rs m3,184607 524.4%   
Net fx Rs m1,219357 341.4%   
CASH FLOW
From Operations Rs m2,4371,345 181.2%  
From Investments Rs m-6,265-2,256 277.7%  
From Financial Activity Rs m2,490-1,200 -207.5%  
Net Cashflow Rs m-1,337-2,111 63.4%  

Share Holding

Indian Promoters % 82.7 4.5 1,825.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 0.0 -  
FIIs % 5.5 1.4 407.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 94.1 8.0%  
Shareholders   10,665 20,807 51.3%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   ABBOTT INDIA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ASTRAZENECA PHARMA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS